EMBC Annual Report 2005
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Reinhart Heinrich (1946–2006) Pioneer in Systems Biology
NEWS & VIEWS NATURE|Vol 444|7 December 2006 OBITUARY Reinhart Heinrich (1946–2006) Pioneer in systems biology. In biology, mathematical systems analysis where he showed that the flux of was until recently nearly invisible in the reaction was shared by several the dazzling light of twentieth-century enzymes. Much later, he extended discoveries. But it has emerged from the his ideas to signal-transduction shadows in the field of systems biology, pathways, introducing control a subject buoyed by immense data sets, coefficients to dynamic processes. conveyed by heavy computing power, and Sticking to real examples, such as addressing seemingly incomprehensible the Wnt signalling and MAP kinase forms of complexity. If systems biology has pathways, he again demonstrated heroes, one of them is Reinhart Heinrich, a that new properties and constraints former professor at the Humboldt University emerge when the individual steps in Berlin, who died on 23 October, aged are combined into a complete 60. His most famous accomplishment was pathway. metabolic control theory, published in Heinrich also pointed the way to 1974 with Tom Rapoport and formulated considerations of optimality theory independently by Henrik Kacser and James and evolution that will confront A. Burns in Edinburgh, UK. systems biology for the next From the 1930s to the 1960s, biochemists century. The question of evolution were busy describing metabolic pathways, lies just beneath any effort to just as molecular biologists today are understand biology. Yet in most feverishly trying to inventory the cell’s cases, physiological function and gene-transcription and signalling circuits. evolutionary change are considered The basic kinetic features of the enzymes in distinct and are investigated by the major pathways were studied in great different people. -
May 29, 1990, NIH Record, Vol. XLII, No. 11
May 29, 1990 Vol. XLII No. l l "The Second U.S. Department of Health Best Thing and Human Services About Payday" National Institutes o f Health e Recori Free Time and Services Given Nill Docs Answer Call to Help The Needy of Washington By Anne Barber A cry for help was mailed recently to hundreds of local physicians residing in the Washingt0n area asking for aid in caring for the needy by volunteering rime and services co che Zacchaeus Medical Clinic. That letter was signed by Dr. Allen L. Dollar, a volunteer physician at the clinic and a senior staff fellow working in NHLBI's Pathology Brand1. Dollar has worked at the clinic, on and off, for the past 13 ye11rs. He began volunteering while an undergraduate student at Georgetown University and worked there for 4 years as a physician's assistant before going off tO medi cal school in Baltimore. Returning to the Washington area 4 years ago, he rejoined the clinic. Zacchaeus is a private, nonprofit clinic operated entirely on private donations. le provides free physician visits, free laborat0ry A 111()unted member of the U.S. Park Police makes his way thrOtifl.h a a-owd of about I, 000 protesters out work and free medication co the poor. side Bid_~. 31 during a demomtration May 21 by fl,ay rights activists. Police arrested 82 people both 011 "When I joined the clinic in 1977, che ca111p11s and al an NTH rental buildinfl, in Rockville. majority of the patients were prostitutes from rhe 14th St. corridor and homeless people 'S wrm the NIH' from the nearby shelters," says Dollar. -
Implications for Optimal Distributions of Enzyme Concentrations and for the Distribution of flux Control
BioSystems 54 (1999) 1–14 www.elsevier.com/locate/biosystems Competition for enzymes in metabolic pathways: Implications for optimal distributions of enzyme concentrations and for the distribution of flux control Edda Klipp *, Reinhart Heinrich Humboldt Uni6ersity Berlin, Institute of Biology, Theoretical Biophysics, In6alidenstr. 42, D-10115, Berlin, Germany Received 1 February 1999; accepted 25 April 1999 Abstract The structures of biochemical pathways are assumed to be determined by evolutionary optimization processes. In the framework of mathematical models, these structures should be explained by the formulation of optimization principles. In the present work, the principle of minimal total enzyme concentration at fixed steady state fluxes is applied to metabolic networks. According to this principle there exists a competition of the reactions for the available amount of enzymes such that all biological functions are maintained. In states which fulfil these optimization criteria the enzyme concentrations are distributed in a non-uniform manner among the reactions. This result has conse- quences for the distribution of flux control. It is shown that the flux control matrix c, the elasticity matrix o, and the vector e of enzyme concentrations fulfil in optimal states the relations cTe=e and o Te=0. Starting from a well-balanced distribution of enzymes the minimization of total enzyme concentration leads to a lowering of the SD of the flux control coefficients. © 1999 Elsevier Science Ireland Ltd. All rights reserved. Keywords: Metabolic control theory; Evolutionary optimization; Competition; Enzyme concentrations; Flux control coefficient; Metabolic pathway; Mathematical modeling 1. Introduction optimal manner. On this basis one can draw conclusions about the actual states of metabolic The structural properties of metabolic systems systems using optimization criteria. -
EMBC Annual Report 2007
EMBO | EMBC annual report 2007 EUROPEAN MOLECULAR BIOLOGY ORGANIZATION | EUROPEAN MOLECULAR BIOLOGY CONFERENCE EMBO | EMBC table of contents introduction preface by Hermann Bujard, EMBO 4 preface by Tim Hunt and Christiane Nüsslein-Volhard, EMBO Council 6 preface by Marja Makarow and Isabella Beretta, EMBC 7 past & present timeline 10 brief history 11 EMBO | EMBC | EMBL aims 12 EMBO actions 2007 15 EMBC actions 2007 17 EMBO & EMBC programmes and activities fellowship programme 20 courses & workshops programme 21 young investigator programme 22 installation grants 23 science & society programme 24 electronic information programme 25 EMBO activities The EMBO Journal 28 EMBO reports 29 Molecular Systems Biology 30 journal subject categories 31 national science reviews 32 women in science 33 gold medal 34 award for communication in the life sciences 35 plenary lectures 36 communications 37 European Life Sciences Forum (ELSF) 38 ➔ 2 table of contents appendix EMBC delegates and advisers 42 EMBC scale of contributions 49 EMBO council members 2007 50 EMBO committee members & auditors 2007 51 EMBO council members 2008 52 EMBO committee members & auditors 2008 53 EMBO members elected in 2007 54 advisory editorial boards & senior editors 2007 64 long-term fellowship awards 2007 66 long-term fellowships: statistics 82 long-term fellowships 2007: geographical distribution 84 short-term fellowship awards 2007 86 short-term fellowships: statistics 104 short-term fellowships 2007: geographical distribution 106 young investigators 2007 108 installation -
EMBO Facts & Figures
excellence in life sciences Reykjavik Helsinki Oslo Stockholm Tallinn EMBO facts & figures & EMBO facts Copenhagen Dublin Amsterdam Berlin Warsaw London Brussels Prague Luxembourg Paris Vienna Bratislava Budapest Bern Ljubljana Zagreb Rome Madrid Ankara Lisbon Athens Jerusalem EMBO facts & figures HIGHLIGHTS CONTACT EMBO & EMBC EMBO Long-Term Fellowships Five Advanced Fellows are selected (page ). Long-Term and Short-Term Fellowships are awarded. The Fellows’ EMBO Young Investigators Meeting is held in Heidelberg in June . EMBO Installation Grants New EMBO Members & EMBO elects new members (page ), selects Young EMBO Women in Science Young Investigators Investigators (page ) and eight Installation Grantees Gerlind Wallon EMBO Scientific Publications (page ). Programme Manager Bernd Pulverer S Maria Leptin Deputy Director Head A EMBO Science Policy Issues report on quotas in academia to assure gender balance. R EMBO Director + + A Conducts workshops on emerging biotechnologies and on H T cognitive genomics. Gives invited talks at US National Academy E IC of Sciences, International Summit on Human Genome Editing, I H 5 D MAN 201 O N Washington, DC.; World Congress on Research Integrity, Rio de A M Janeiro; International Scienti c Advisory Board for the Centre for Eilish Craddock IT 2 015 Mammalian Synthetic Biology, Edinburgh. Personal Assistant to EMBO Fellowships EMBO Scientific Publications EMBO Gold Medal Sarah Teichmann and Ido Amit receive the EMBO Gold the EMBO Director David del Álamo Thomas Lemberger Medal (page ). + Programme Manager Deputy Head EMBO Global Activities India and Singapore sign agreements to become EMBC Associate + + Member States. EMBO Courses & Workshops More than , participants from countries attend 6th scienti c events (page ); participants attend EMBO Laboratory Management Courses (page ); rst online course EMBO Courses & Workshops recorded in collaboration with iBiology. -
Annual Report and Accounts 2007-08
07/08 Annual report and accounts Medical Research Council Annual Report and Accounts 2007/08 Presented to Parliament by the Secretary of State for Innovation, Universities and Skills, and by the Comptroller and Auditor General in pursuance of Schedule I, Sections 2(2) and 3(3) of the Science and Technology Act 1965. Sir John Chisholm Chairman Sir Leszek Borysiewicz Deputy Chairman and Chief Executive Ordered by the House of Commons and printed on London: The Stationery Office 21 July 2008 Price: £18.55 HC 904 © Crown Copyright 2008 The text in this document (excluding the Royal Arms and other departmental or agency logos) may be reproduced free of charge in any format or medium providing it is reproduced accurately and not used in a misleading context. The material must be acknowledged as Crown copyright and the title of the document specified. Where we have identified any third party copyright material you will need to obtain permission from the copyright holders concerned. For any other use of this material please write to Office of Public Sector Information, Information Policy Team, Kew, Richmond, Surrey TW9 4DU or e-mail: [email protected] ISBN:978 0102956993 ANNUAL REPORT 2007/08 CONTENTS The Medical Research Council 4 Executive Summary 6 Foreword 10 Strategic coordination: MRC and NIHR in partnership 14 Delivering knowledge 16 Translating discovery 24 Developing people 32 Working in partnership 38 Public engagement 44 Promoting best practice in research 50 Supporting research excellence 54 Increasing business effectiveness 60 Management Commentary 2007/08 64 Remuneration Report 2007/08 70 Annual Accounts 2007/08 76 THE MEDICAL RESEarcH COUNCIL The Medical Research Council (MRC) is a publicly-funded organisation dedicated to improving human health. -
Cv from Public Relations
PROF. RUTH ARNON Formerly Vice-President of the Weizmann Institute of Science (1988-1997), is a world renowned Immunologist. Prof. Arnon joined the Weizmann Institute in 1960. Prior to her appointment as Vice-President, she served as Head of the Department of Chemical Immunology, and as Dean of the Faculty of Biology. From 1985 to 1994, she was the Director of the Institute's MacArthur Center for Molecular Biology of Tropical Diseases. Prof. Arnon has made significant contributions to the fields of vaccine development, cancer research and to the study of parasitic diseases. Along with Prof. Michael Sela, she developed Copaxone® a drug for the treatment of multiple sclerosis which was approved by the U.S. Food and Drug Administration, and is presently marketed in the USA, Canada the EU, Australia and many other countries worldwide. Prof. Arnon is a member of the Israel Academy of Sciences, and was the Chairperson of its Sciences division from 1995-2001 and was later elected as The Academy's Vice President. On the world scene, she is an elected member of the European Molecular Biology Organization (EMBO). She has served as President of the European Federation of Immunological Societies (EFIS), and as Secretary-General of the International Union of Immunological Societies (IUIS), and is presently a member of the European Union Research Advisory Board (EURAB) and served as the Senior Vice-President of the Association of Academies of Sciences in Asia (AASA). In 2004 Prof. Arnon served as the President of the Association of Academies of Sciences in Asia (AASA). Her awards include the Robert Koch Prize in Medical Sciences, Spain's Jiminez Diaz Memorial Prize, France's Legion of Honor, the Hadassah World Organization's Women of Distinction Award, the Wolf Prize for Medicine, the Rothschild Prize for Biology and the Israel Prize; Tel-Hai; Honorary doctorate from the University of the Negev, Ben- Gurion. -
Metastasis and Invasion 3 – Metastasis Science Cancer
CANCER SCIENCE 3 Cancer Science 3 – Metastasis and Invasion 3 – Metastasis Science Cancer www.ipsen.com 2FI 0069 Metastasis and Invasion Tuscany, May 20-23, 2007 24, rue Erlanger – 75016 Paris – Tel.: 33(0)1 44 96 10 10 – Fax: 33(0)1 44 96 11 99 COLLOQUES MÉDECINE ET RECHERCHE Fondation Ipsen SCIENTIFIC REPORT BY APOORVA MANDAVILLI 2 Fondation Ipsen is placed under the auspices of Fondation de France MOLECULAR MARKERS 3 4 Foreword by Inder M. Verma 7 Part I: Molecular markers 9 J. Michael Bishop Senescence and metastasis in mouse models of breast cancer 15 Joan Massagué Metastasis genes and functions 21 Zena Werb Transcriptional regulation of the metastatic program 25 Inder M. Verma BRCA1 maintains constitutive heterochromatin formation: a unifying hypothesis of its function 29 Tak Wah Mak The role of RhoC in development and metastasis 35 Part II: Motility and invasiveness 37 Robert Weinberg Mechanisms of malignant progression 43 Daniel Louvard Fascin, a novel target of b-catenin-Tcf signaling, is expressed at the invasive front of human colon cancer 49 Gerhard Christofori Distinct mechanisms of tumor cell invasion and metastasis 55 Douglas Hanahan Multiple parameters influence acquisition by solid tumors CONTENTS of a capability for invasive growth 59 Part III : Mechanisms of metastasis 61 Richard Hynes Cellular mechanisms contributing to metastasis 67 Ann Chambers Novel imaging approaches for studying tumor metastasis 73 Jeffrey Pollard Macrophages are a cellular toolbox that tumors sequester to promote their progression to malignancy 79 Wolf-Hervé Fridman T effector/memory cells, the ultimate control of metastasis in humans 85 Kari Alitalo Inhibition of lymphangiogenesis and metastasis 91 Shahin Rafii Contribution of CXCR4+VEGFR1+ pro-angiogenic hematopoietic cells to tumor oncogenesis 97 Part IV : Cancer stem cells 99 Paolo Comoglio Invasive growth : a MET-driven genetic program for cancer and stem cells 105 Hans Clevers Wnt and Notch cooperate to maintain proliferative compartments in crypts and intestinal neoplasia 111 Owen N. -
Redundancy and Specificity F Mechta-Grigoriou Et Al 2379
Oncogene (2001) 20, 2378 ± 2389 ã 2001 Nature Publishing Group All rights reserved 0950 ± 9232/01 $15.00 www.nature.com/onc The mammalian Jun proteins: redundancy and speci®city Fatima Mechta-Grigoriou1, Damien Gerald1 and Moshe Yaniv*,1 1Unite des virus oncogenes, CNRS URA 1644, Institut Pasteur, 25 rue du Docteur Roux, 75724 Paris Cedex 15, France The AP-1 transcription factor is composed of a mixture transcription factors. These proteins are characterized of homo- and hetero-dimers formed between Jun and Fos by a highly charged, basic DNA binding domain, proteins. The dierent Jun and Fos family members vary immediately adjacent to an amphipathic dimerization signi®cantly in their relative abundance and their domain, referred as the `Leucine zipper' (Kouzarides interactions with additional proteins generating a and Zi, 1988; Landschulz et al., 1988). Dimerization complex network of transcriptional regulators. Thus, is required for speci®c and high anity binding to the the functional activity of AP-1 in any given cell depends palindromic DNA sequence, TGAC/GTCA (Rauscher on the relative amount of speci®c Jun/Fos proteins which et al., 1988; Gentz et al., 1989; Hirai and Yaniv, 1989; are expressed, as well as other potential interacting Ransone et al., 1989; Schuermann et al., 1989; Turner proteins. This diversity of AP-1 components has and Tjian, 1989). The dierent AP-1 dimers exhibit complicated our understanding of AP-1 function and similar DNA binding speci®cities but dier in their resulted in a paucity of information about the precise transactivation eciencies (Chiu et al., 1989; Hirai et role of individual AP-1 members in distinct cellular al., 1990; Kerppola and Curran, 1991b; Suzuki et al., processes. -
NEWSLETTER – March 2016
BRITISH SOCIETY FOR PROTEOME RESEARCH www.bspr.org UK Charity Number 1121692 Registered Company No.6319769 NEWSLETTER – March 2016 BSPR 2016 – PROTEOMIC APPROACHES TO HEALTH AND DISEASE University of Glasgow – 25-27 July 2016 th th The 2016 meeting of the Society will be held in the Western Infirmary Lecture Theatre building from Mon 25 – Wed 27 July 2016. For up to date information: (www.bspr.org/node/527) Abstract submission now open. Deadline: Mon 6th May. Registration opening shortly! Speakers include: Plenary - Matthias Mann – Max-Planck Institute for Biochemistry, Martinsried (GER) Rob Beynon (BSPR Lecturer 2016) – University of Liverpool (UK) Keynote: -Cancer: Judit Villen – University of Washington, Genome Sciences (US) Integration Omics: David Matthews – University of Bristol (UK) Metabolic disease: Harald Mischak – University of Glasgow (UK) Development and ageing: Xavier Druart - French Nat’l Inst for Agricultural Res, Nouzilly (FR) Nutrition/Lifestyle & Food Security: David Eckersall - University of Glasgow (UK) Infectious disease and Microbiome: Frank Schmidt – University of Greifswald (GER) New Technologies - Matthias Hentze – EMBL Heidelberg (GER) Data Analysis – Maria Martin – EMBL-EBI Cambridge (UK) Translation – Chris Sander, New York (US) More than 20 abstracts will be selected for oral presentation! Bursaries and Awards BSPR 2016 - The Society will be awarding the MJ Dunn Fellowship for attendance at BSPR 2016, and will also be awarding Bursaries to student members (£250) to enable them to attend a conference of their choice, including BSPR 2016. 10th European Summer School EMBO Workshop “Advanced Proteomics”, July 31st – August 6th, 2016. The Society will be awarding one or two bursaries (residential registration fee) to student members to enable them attend this workshop which will be held in Kloster Neustift, Brixen/Bressanone, South Tyrol, Italy. -
The Helicase Ded1p Controls Use of Near-Cognate Translation Initiation Codons in 5Utrs
The helicase Ded1p controls use of near- cognate translation initiation codons in 5# UTRs The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Guenther, Ulf-Peter et al. "The helicase Ded1p controls use of near- cognate translation initiation codons in 5# UTRs." Nature 559, 7712 (June 2018): 130–134. © 2018 Macmillan Publishers Ltd., part of Springer Nature As Published http://dx.doi.org/10.1038/s41586-018-0258-0 Publisher Springer Science and Business Media LLC Version Author's final manuscript Citable link https://hdl.handle.net/1721.1/125996 Terms of Use Creative Commons Attribution-Noncommercial-Share Alike Detailed Terms http://creativecommons.org/licenses/by-nc-sa/4.0/ HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Nature. Manuscript Author Author manuscript; Manuscript Author available in PMC 2018 December 27. Published in final edited form as: Nature. 2018 July ; 559(7712): 130–134. doi:10.1038/s41586-018-0258-0. The helicase Ded1p controls use of near-cognate translation initiation codons in 5′UTRs Ulf-Peter Guenther1,*, David E. Weinberg2,3,*, Meghan M. Zubradt2,4,*, Frank A. Tedeschi1, Brittany N. Stawicki1, Leah L. Zagore1, Gloria A. Brar5, Donny D. Licatalosi1, David P. Bartel3, Jonathan S. Weissman2,4, and Eckhard Jankowsky1,6,7 1Center for RNA Science and Therapeutics, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA 2Department of Cellular and Molecular Pharmacology, University of California, -
A N N U a L R E P O R T 2 0
0 1 0 2 Acknowledgements T R HFSPO is grateful for the support of the following organizations: O P Australia E R National Health and Medical Research Council (NHMRC) L Canada A Canadian Institute of Health Research (CIHR) U Natural Sciences and Engineering Research Council (NSERC) N European Union N European Commission - A Directorate General Information Society (DG INFSO) European Commission - Directorate General Research (DG RESEARCH) France Communauté Urbaine de Strasbourg (CUS) Ministère des Affaires Etrangères et Européennes (MAEE) Ministère de l’Enseignement Supérieur et de la Recherche (MESR) Région Alsace Germany Federal Ministry of Education and Research (BMBF) India Department of Biotechnology (DBT), Ministry of Science and Technology Italy Ministry of Education, University and Research (CNR) Japan Ministry for Economy, Trade and Industry (METI) Ministry of Education, Culture, Sports, Science and Technology (MEXT) Republic of Korea Ministry of Education, Science and Technology (MEST) New Zealand Health Research Council (HRC) Norway Research Council of Norway (RCN) Switzerland State Secretariat for Education and Research (SER) United Kingdom The International Human Frontier Science Biotechnology and Biological Sciences Research Program Organization (HFSPO) Council (BBSRC) 12 quai Saint Jean - BP 10034 Medical Research Council (MRC) 67080 Strasbourg CEDEX - France Fax. +33 (0)3 88 32 88 97 United States of America e-mail: [email protected] National Institutes of Health (NIH) Web site: www.hfsp.org National Science Foundation (NSF) Japanese web site: http://jhfsp.jsf.or.jp HUMAN FRONTIER SCIENCE PROGRAM The Human Frontier Science Program is unique, supporting international collaboration to undertake innovative, risky, basic research at the frontiers of the life sciences.